Are biopsy specimens predictive of HER2 status in gastric cancer patients?

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 397-404

  Pirrelli, M ^a   Caruso, M L ^a   Di Maggio, M ^a   Armentano, R ^a   Valentini, A M ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

CISH; Gastric cancer; HER2; Immunohistochemistry; Molecular targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECISION MAKING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; BIOPSY; CLINICAL TRIAL; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; STANDARD; STOMACH TUMOR; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOPSY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84876337887     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2357-3     Document Type: Article

References (42)

1. Kamagar F, Dores GM, Anderson WF. Pattern of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present and future. J Gastroenterol. 2008;43:256-264.
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644-1646.
4. Coussens L, Yang-feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1339.
5. Kaptain S, Tan LK, Chen B. HER2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139-152.
6. Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.
7. Eltze E, Wulfing C, Von Struensee D, Piechota H, Buerger H, Hertle L. HER2/neu co-expression in invasive bladder cancer. Int J Oncol. 2005;26:1525-1531.
8. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992;47:179-185.
9. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33.
10. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
11. Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-129.
12. Hofmann M, Stoss O, Shi D, et al. Assessment of HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
13. Marx AH, Tharun L, Muth J, et al. Her-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769-777.
14. Grabsh H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two indipendent series. Cell Oncol. 2010;32:57-65.
15. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372-1376.
16. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
17. Tanner M, Gancberg BA, Leo AD, et al. Chromogenic in situ hybridization: a practical alternative for fluorescece in situ hybridization to detect HER2/neu oncogene in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
18. Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657-665.
19. Peanault-Llorca F, Chenard MP, Bouchè O, et al. HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011. Ann Pathol. 2011;31:78-87.
20. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostic in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307.
21. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with Trastuzumab. Breast Cancer Res Treat. 2005;93:3-11.
22. Press M, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
23. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HERE2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15:65-71.
24. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59:832-840.
25. Yang J, Luo H, Li J, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62:221-228.
26. Dowsett M, Bartlett J, Ellis I, et al. Correlation between immunohistochemistry (Herceptest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
27. Lal P, Salazar P, Hudis C, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. A single institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631-636.
28. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469-6487.
29. Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer. 1991;64:79-83.
30. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 1990;50:8002-8029.
31. Cottu PH, Asselah J, Lae M, et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol. 2008;19:595-597.
32. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer. Arch Pathol Lab Med. 2009;133:611-612.
33. Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol. 2010;28:3264-3270.
34. Tamaki K, Sasano H, Ishida E, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010;101:2074-2079.
35. Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Oamura RY. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer. 2010;10:534.
36. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20:1948-1952.
37. Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in brest carcinoma determined by core needle biopsies. Jpn J Clin Oncol. 2007;37:250-255.
38. Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17:1501-1506.
39. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
40. Kim MA, Lee H-J, Yang H-K, Bang Y-J, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822-831.
41. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of ERBB2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552-556.
42. Rossi E, Villanacci V, Basotti G, et al. TOPOIIα and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology. 2010;57:81-89.